Clinical efficacy of Bambuterol alone and in combination with Borage & Echium seed oil in chronic persistent asthma

Syed Saud Hasan; Moosa Khan; Musarrat Sultana; Asif Iqbal; Shamsul Arfin Qasmi

Authors

Syed Saud Hasan Chairman Pharmacology, Dow University of Health Sciences, Karachi
Moosa Khan Head of Department of Pharmacology, Pakistan Institute of Medical Sciences, Islamabad
Musarrat Sultana Associate Professor, Forensic Medicine, DIMC, Dow University of Health Sciences, Karachi
Asif Iqbal Chairman Eastern Medicine, Hamdard University, Karachi
Shamsul Arfin Qasmi Department of Pathology & Microbiology, Karachi Institute of Medical Sciences (KIMS), Malir Cantt. Karachi, Pakistan

Keywords:

Asthma, Bambuterol, Borage/Echium seed oil, Spirometry, PEFR, Questionnaire

Abstract

Introduction: Asthma chronic inflammatory disease, highly prevalent all ages, characterizes by cough, dyspnea, chest tightness, wheezing & impairment in physical activities. Inflammatory cells degranulation, release of numbers of mediators and toxic substances, leukotriene’s are consider important. Bambuterol, reducing the frequency of recurrent episodes of bronchospasm and Borage & Echium seed oil, inhibits the leukotriene’s generation & competing with the arachidonic acid, thus decreasing the inflammatory process.

Objective: To evaluate the clinical efficacy of Bambuterol alone and in combination with Borage & Echium seed oil in chronic persistent asthma.

Method & Materials: An interventional study, approved by BASR University of Karachi. Group-A, Bambuterol oral once daily & Group B, Bambuterol once daily & Borage seed oil 1.3 gram daily plus Echium seed oil 500mg twice daily for 90 days. Diagnosed 120-registered patients, 60 patients in each group completed study period, results compared by Spirometry, PEFR, daily symptoms diary card and clinical questionnaires evaluated statistically.

Results: Group-A at day-90, percentage change of FEV₁ 4.7%, FVC 5.9%, PEFR 7.1%. Group-B, FEV₁ 13.3%, FVC 9.2%, PEFR 15.2%, results are statistically highly significant. Symptoms improvement and reduction in night sleep awakening, decreased need of recue medicine. Drug safety was determined by observing reported adverse effects on serum level of Alkaline Phosphatase, SGPT, Cholesterol, HDL, LDL and compliance of drug was checked by follow up at day-30, 60 & 90 and in between daily symptom dairy card.

Conclusion: Improvement reported by mean of, reduced severity, improved clinical symptoms & quality of life and no serious adverse effects, results are highly significant. Combination therapy provided synergistic effect.